News

When you look back at a 45-year career, there are a multitude of moments that stand out. For Allan Butterfield, Professor of Biological Chemistry in the UK College of Arts & Sciences, his signature discovery grew from just such a Eureka moment on the sidewalk on campus. 

“I can’t advocate for someone unless I’m working with them. It’s presumptuous to say, ‘I know what you need,’” Kitzman said. “The moment we at KARRN start working with someone, we agree to be their advocate and do whatever it takes to find resources for them.”

A pilot grant from UK’s Center for Clinical and Translational Science (CCTS) will advance neuroscience researcher George Quintero’s studies on Parkinson’s disease to a clinical investigation.

"I really just developed a love for the campus." Mark Lovell credits a history of collaboration at UK for driving his research for the past 30 years.

Researchers at UK's College of Medicine have found that a class of antibiotics could be promising treatment for a form of dementia. Results of their proof of concept study were recently published in the journal Human Molecular Genetics.

The UK College of Medicine will host the 2019 Obstetrical Neurology Conference on Friday, Sept. 6, 2019 for faculty, providers and trainees in neurology, obstetrics, anesthesia and women's health interested in neurological issues in the pregnant patient.

Thanks to volunteers, SBCoA has played a role in many landmark discoveries, including debunking the theories that aluminum or mercury cause Alzheimer's, identifying so-called "AD mimics", and proving that there are changes in the brain decades before there are outward symptoms of AD.

A team of scientists have designed and tested a novel and promising therapeutic strategy for treating Lafora Disease (LD), a fatal form of childhood epilepsy.

Faculty from the Dept of Psychology in the College of Arts & Sciences and Behavioral Science in the College of Medicine have received two, five-year Research Project Grants from the NIH to study neurobehavioral processes involved in drug use disorders.

In an editorial published in CNS Spectrums, UK Neurologist Jay Avasarala, MD, PhD, takes the research community to task for its lack of minority representation in Phase III clinical trials for drugs to treat Multiple Sclerosis (MS).